Sirtris Pharmaceuticals Inc.

Another hot stock is Sirtris Pharmaceuticals. The startup’s activity is discovering and developing proprietary, orally available, small molecule drugs with the potential to treat  metabolic diseases such as Type 2 Diabetes and such of aging by modulating sirtuins, a recently discovered class of enzymes. The drug candidates are designed to mimic certain beneficial health effects of calorie restriction, without requiring a change in eating habits, by activating an enzyme called SIRT1, a member of a recently discovered class of enzymes called sirtuins.

All in all Sirtris (NASDAQ:SIRT) is a promising investment in two ways: first its activities are in a field that affects everyone of us sooner or later. Secondly it has just a market capitalization of 340 million dollars – but its competitors are Pfizer (market cap: 152b $), Johnson & Johnson (180 b) and Eli Lilly (58 b). You get the point. One buyout offer and the stock shoots into the sky.

ETFC : E*Trade rebound

Sometimes it pays out not to be a chicken. After realizing that E*Trade (NASDAQ:ETFC) was just a pinball in the game of Prashant Bhatia, the wizzard of Citibank, I was tempted to buy this stock but chickened out when it hit 2,-$.

A biiiig mistake though I was convinced that price was definetly way too low – but there was the danger of foreign fulfilling prophecy: if a guy like that Bhatia from Citi could bring a stock that much down just by blubbering E*Trade could go bankrupt though he had no data to project this – who knew what could happen next? The stock could’ve gone to zero.

So, instead of risking at least only 2.000,- $ I did nothing. Stupid me. But that’s the way it is: when fear switches off reason. Well, in the end I went in at 3,- $ so it’s not soo bad. I just don’t know yet if I should go long or not since the technical analysis shows a clear upward trend.

I could imagine that the stock will see double digits within the next months. But I hesitate to engage heavily.